ARQ 197 in patients with previously-treated malignant mesothelioma (MM): A phase II trial from the University of Chicago Phase II Consortium.

7511 Background: The MET receptor tyrosine kinase plays a key role in MM biology. MET and its ligand, hepatocyte growth factor (HGF), are each over-expressed in ~80% of MM; MET is mutated and/or am...